|Over a quarter ago|
Two new option listings and four option delistings on November 1st » 08:3011/0111/01/19
CEMI, CUR, HPJ, UBNK
New option listings for…
New option listings for November 1st include Chembio Diagnostics (CEMI) and Seneca Biopharma Inc (SNCA). Option delistings effective November 1st include Bristow Group Inc (BRSWQ), Neuralstem Inc (CUR), Highpower International Inc (HPJ), and United Financial Bancorp Inc (UBNK).
Seneca Biopharma, QYuns Therapeutics sign licensing agreement » 07:4410/3010/30/19
Seneca Biopharma, (fka…
Seneca Biopharma, (fka Neuralstem) and Jiangsu QYuns Therapeutics Co., a China-based company focused on monoclonal antibody therapeutics, jointly announce that they have entered into a non-binding term sheet for the licensing of certain assets owned by QYuns. Subject to entering into definitive agreements and receiving necessary approvals, Seneca and QYuns will enter into a royalty- and milestone-free, perpetual, non-cancelable, exclusive worldwide, other than in Greater China (which includes Hong Kong, Macau and Taiwan and certain other Asian territories) license to develop and commercialize certain of QYuns' assets, including QX005N, targeting IL-4Ralpha, QX002N, targeting IL-17A, QX004N targeting IL-23A, and QX006N targeting IFNRalpha. As contemplated by the term sheet, Seneca will also gain access to future antibody assets developed by QYuns and the parties will collaborate on future pipeline expansion. Upon entering into the license, Seneca's lead asset will be SNC005 that targets IL-4Ralpha for the treatment of Asthma and Atopic Dermatitis. As consideration for the license, Seneca will issue QYuns a yet to be determined amount of common stock.
Neuralstem changes name to Seneca Biopharma » 09:1110/2810/28/19
Neuralstem announces that…
Neuralstem announces that the company has changed its name to Seneca Biopharma. The company anticipates that its shares will begin trading on the NASDAQ Capital Market under the symbol SNCA on November 1 or shortly thereafter subject to the satisfaction of customary conditions of the exchange.
Neuralstem: Last subject enrolled in Phase 2 clinical trial of NSI-566 » 07:3109/2409/24/19
Neuralstem announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic ischemic stroke. NSI-566 is Neuralstem's lead stem cell therapy candidate, and has also been evaluated in clinical trials for patients with Amyotrophic Lateral Sclerosis and chronic spinal cord injury. The trial is being conducted at the BaYi Brain Hospita in Beijing, China under the direction of Professor Xu Ruxiang.
Neuralstem granted Nasdaq hearings panel request for continued listing » 07:3808/0708/07/19
Neuralstem received a…
Neuralstem received a letter from Nasdaq informing the company that the Nasdaq Hearings Panel has granted the company's request for continued listing of the company's stock on Nasdaq. The Panel found that the company had (i) demonstrated compliance with the bid price requirement and (ii) addressed the Panel's questions regarding its stockholders' equity position and will continue its listing and that the matter is closed.
Fly Intel: Pre-market Movers » 09:0307/2607/26/19
GOOG, GOOGL, AMZN, MCD, SBUX, TWTR, ABBV, INTC, VNE, ITW, CHTR, LEA, CUR, TYPE
UP AFTER EARNINGS:…
UP AFTER EARNINGS: Alphabet (GOOGL), up 9%... McDonald's (MCD), up 2%... Twitter (TWTR), up 6%... AbbVie (ABBV), up 2%... Intel (INTC), up 4%... Veoneer (VNE), up 5%... Starbucks (SBUX), up 6%. ALSO HIGHER: Monotype Imaging (TYPE), up 23% after announcing that it has entered into an agreement to be acquired for $19.85 per share in cash, representing an aggregate equity value of approximately $825M. DOWN AFTER EARNINGS: Amazon (AMZN), down 1.5%... Illinois Tool Works (ITW), down 4%... Charter (CHTR), down 6%... Lear (LEA), down 4%. LOWER: Neuralstem (CUR), down 40% after its 2.778M share secondary offering priced at $2.70 per share.
Neuralstem 2.778M share Secondary priced at $2.70 » 06:2507/2607/26/19
H.C. Wainwright acted as…
H.C. Wainwright acted as sole book running manager for the offering.
Neuralstem announces 1-for-20 reverse stock split » 07:3107/1607/16/19
Neuralstem announced a…
Neuralstem announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective on Wednesday, July 17 after market close and shares of Neuralstem Inc. common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "CUR," at the market open on Thursday, July 18. The reverse stock split enables Neuralstem to regain compliance with the $1.00 minimum bid price condition of the NASDAQ Capital Market continued listing requirements.